PATENT CLAIM ANALYSIS

Application Number: 16085234
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "130100"]

Abstract:
The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).

Claim (Index 16):
The human immunoglobulin preparation for use according to  claim 1 , wherein said immunoglobulin preparation is administered according to the following treatment regimen: a first daily dose to be administered within 24 hours, preferably between 1 and 12 hours after start of vasopressor therapy and/or invasive mechanical ventilation, followed by 3 to 10, preferably 3 to 6, consecutive daily infusions, and optionally one or more maintenance infusions at 10 to 18 days after the first administration with said immunoglobulin preparation.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13817414', '14529400', '13655686', '15348121', '14778114']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6830827646718618
- 35 USC 102 Novelty (BERT): 0.5126131499973744
- Combined Prediction Score: 0.666035803204413
- Mean Citation Score: 230.49716
- Max Citation Score: 256.71954
- Similarity Product: 180.4056546731937

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test